Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) has received an average rating of “Buy” from the twelve research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $53.50.
A number of equities analysts recently weighed in on GMAB shares. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, November 9th. Guggenheim upped their price target on Genmab A/S from $58.00 to $80.00 and gave the company a “buy” rating in a report on Friday, October 30th. Morgan Stanley dropped their price objective on Genmab A/S from $57.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, November 13th. JPMorgan Chase & Co. upgraded shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a research note on Monday, October 26th. Finally, HC Wainwright raised their price target on shares of Genmab A/S from $50.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, October 29th.
Check Out Our Latest Research Report on GMAB
Institutional Investors Weigh In On Genmab A/S
Genmab A/S Stock Performance
Shares of Genmab A/S stock opened at $51.35 on Friday. The stock has a market cap of $32.05 billion, a price-to-earnings ratio of 43.89, a PEG ratio of 2.05 and a beta of 0.73. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.45 and a quick ratio of 2.43. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $59.97. The firm’s 50-day moving average is $42.62 and its 200 day moving average is $31.97.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.20. Genmab A/S had a net margin of 16.97% and a return on equity of 13.67%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.20 billion. Sell-side analysts anticipate that Genmab A/S will post 1.28 EPS for the current fiscal year.
About Genmab A/S
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
Featured Stories
- Five stocks we like better than Genmab A/S
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
